Andere talen XOMA Corporation

Aandelen

XOMA

US98419J2069

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
25,41 ^USD	+0,20%		-0,27%	+37,35%

03/04	XOMA Corporation (NasdaqGM:XOMA) heeft de overname afgerond van Kinnate Biopharma Inc. (NasdaqGS:KNTE).	CI
08/03	XOMA Corporation rapporteert resultaten voor het gehele jaar eindigend op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)	25/04
XOMA : Acquisition/Asset Disposal - Form 8-K	03/04
XOMA Corporation Announces Closing of Tender Offer	03/04
XOMA Corporation completed the acquisition of Kinnate Biopharma Inc..	03/04
XOMA Declares Quarterly Preferred Stock Dividends	21/03
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.	19/03
Xoma: Q4 Earnings Snapshot	08/03
XOMA Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	08/03
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value	08/03
XOMA to Present at Upcoming Investor Conferences in March	28/02
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash per Share plus a Contingent Value Right	19/02
Shareholder Alert: Ademi LLP investigates whether Kinnate Biopharma Inc. has obtained a Fair Price in its transaction with XOMA	16/02
Sector Update: Health Care Stocks Advance Friday Afternoon	16/02
XOMA Agrees to Acquire Kinnate Biopharma	16/02
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right	16/02
XOMA Corporation entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. for approximately $120 million.	16/02
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA Acquisition	19/01
XOMA Acquires Interest in Pain Management Medication Dsuvia for $8 Million	18/01
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition	18/01
XOMA Corporation acquired DSUVIA® of Talphera, Inc. for $8 million.	18/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen XOMA Corporation

Aandelen

XOMA

US98419J2069

Andere talen

Filters